DRRX - DURECT Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.04
+0.05 (+4.87%)
As of 3:15PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.99
Open0.97
Bid1.03 x 1400
Ask1.04 x 3500
Day's Range0.97 - 1.05
52 Week Range0.74 - 2.17
Volume535,088
Avg. Volume947,717
Market Cap154.488M
Beta2.14
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube4 days ago

    ETFs with exposure to DURECT Corp. : December 11, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DURECT Corp. Here are 5 ETFs with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube14 days ago

    ETFs with exposure to DURECT Corp. : December 1, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DURECT Corp. Here are 5 ETFs with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube25 days ago

    ETFs with exposure to DURECT Corp. : November 20, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DURECT Corp. Here are 5 ETFs with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • DURECT Corp. :DRRX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
    Capital Cubelast month

    DURECT Corp. :DRRX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017

    Categories: Yahoo FinanceGet free summary analysis DURECT Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of DURECT Corp. – Pain Therapeutics, Inc., Zogenix, Inc., Johnson & Johnson, Pfizer Inc., Eli Lilly and Company, Heron Therapeutics Inc and Pacira Pharmaceuticals, Inc. (PTIE-US, ZGNX-US, JNJ-US, PFE-US, LLY-US, ... Read more (Read more...)

  • Capital Cubelast month

    ETFs with exposure to DURECT Corp. : November 8, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DURECT Corp. Here are 5 ETFs with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Thomson Reuters StreetEventslast month

    Edited Transcript of DRRX earnings conference call or presentation 1-Nov-17 8:30pm GMT

    Q3 2017 DURECT Corp Earnings Call

  • Zacks Small Cap Researchlast month

    DRRX: Focus will be Shifted to DUR-928 Programs

    Revenue from R&D collaborations was $5.6 million in third quarter 2017, compared to $0.4 million in third quarter 2016. A large portion of that increase related to the recognition of deferred revenue from upfront fees already received by the company.

  • Associated Presslast month

    Durect tops Street 3Q forecasts

    On a per-share basis, the Cupertino, California-based company said it had net income of 4 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • Capital Cube2 months ago

    ETFs with exposure to DURECT Corp. : October 26, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DURECT Corp. Here are 5 ETFs with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube2 months ago

    ETFs with exposure to DURECT Corp. : October 16, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DURECT Corp. Here are 5 ETFs with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • DURECT Corp. :DRRX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017
    Capital Cube2 months ago

    DURECT Corp. :DRRX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017

    Categories: Yahoo FinanceGet free summary analysis DURECT Corp. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 4.32 million, Net Earnings of USD -9.93 million. Gross margins widened from 71.08% to 78.61% compared to the same period last year, operating (EBITDA) margins now -214.24% from -265.79%. Change in operating cash ... Read more (Read more...)

  • Zacks Small Cap Research2 months ago

    DURECT (DRRX): A $17.5 Million Patent Purchase Agreement with Indivior PLC

    Pursuant to the agreement, DURECT has assigned certain of its U.S. patent rights to Indivior. This assignment may provide further intellectual property protection for RBP-7000, Indivior's investigational once-monthly injectable risperidone product for the treatment of schizophrenia.  Indivior has submitted a New Drug Application (NDA) for RBP-7000 to the U.S. Food and Drug Administration (FDA).

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of DRRX earnings conference call or presentation 8-Aug-17 8:30pm GMT

    Q2 2017 DURECT Corp Earnings Call

  • Zacks Small Cap Research4 months ago

    DRRX: A $293 Million Deal with Sandoz for POSIMIR® in the United States

    On May 8, 2017, Durect (DRRX) announced a development and commercialization agreement with Sandoz AG, a division of Novartis (NVS), to develop and market in the United States Durect’s POSIMIR® (SABER®-Bupivacaine), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery. Under the terms of the agreement, Sandoz will make an upfront payment to DURECT of $20 million, with the potential for up to an additional $43 million in development and regulatory milestones, up to an additional $230 million in sales based milestones, as well as a tiered double digit royalty on product sales in the United States. The $43 million could be received when Durect resubmits the NDA and get approval for Posimir which could be done in 1Q18.

  • Associated Press4 months ago

    Durect reports 2Q loss

    On a per-share basis, the Cupertino, California-based company said it had a loss of 7 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...

  • Capital Cube5 months ago

    ETFs with exposure to DURECT Corp. : July 10, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DURECT Corp. Here are 5 ETFs with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube7 months ago

    ETFs with exposure to DURECT Corp. : May 26, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DURECT Corp. Here are 5 ETFs with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Thomson Reuters StreetEvents7 months ago

    Edited Transcript of DRRX earnings conference call or presentation 10-May-17 8:30pm GMT

    Q1 2017 DURECT Corp Earnings Call

  • Capital Cube7 months ago

    ETFs with exposure to DURECT Corp. : May 15, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DURECT Corp. Here are 5 ETFs with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • DURECT Corp. :DRRX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
    Capital Cube7 months ago

    DURECT Corp. :DRRX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017

    Categories: Yahoo FinanceGet free summary analysis DURECT Corp. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of DURECT Corp. – Zogenix, Inc., Impax Laboratories, Inc., Johnson & Johnson, Pfizer Inc., Pacira Pharmaceuticals, Inc., Heron Therapeutics Inc, Eli Lilly and Company and Corium International, Inc. (ZGNX-US, IPXL-US, ... Read more (Read more...)

  • Associated Press7 months ago

    Durect reports 1Q loss

    The Cupertino, California-based company said it had a loss of 6 cents per share. The specialty pharmaceutical company posted revenue of $4.6 million in the period. In the final minutes of trading on Wednesday, ...

  • Zacks Small Cap Research7 months ago

    DURECT(DRRX): A $293 Million Deal with Sandoz for POSIMIR® in the United States

    Earlier today (May 8, 2017), Durect  Corporation (DRRX) announced a development and commercialization agreement with Sandoz AG, a division of Novartis (NVS), to develop and market in the United States DURECT's POSIMIR® (SABER®-Bupivacaine), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery. Under the terms of the agreement, Sandoz will make an upfront payment to DURECT of $20 million, with the potential for up to an additional $43 million in development and regulatory milestones, up to an additional $230 million in sales based milestones, as well as a tiered double digit royalty on product sales in the United States.

  • Capital Cube8 months ago

    ETFs with exposure to DURECT Corp. : April 27, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DURECT Corp. Here are 5 ETFs with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Reuters8 months ago

    NASH: The next untapped pharma market gives investors many options

    Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver ...

  • Capital Cube9 months ago

    ETFs with exposure to DURECT Corp. : March 27, 2017

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to DURECT Corp. Here are 5 ETFs with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)